CompanyGraph
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
603456 · SSE · China
jiuzhoupharma.comFinancials as of FY2025
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.26B, above the global median of $1.15B
- FinancialsAltman Z-Score 6.73: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.60%Below 5Y avg (1.85%)
Annual Rate
CNY 0.10Paid annual
Payout Ratio
44.8%Sustainable
Last Ex-Dividend
Jun 11, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
15.22BCNY2.26B · vs all stocks (USD)
Trailing P/E
25.76xRevenue (TTM)
5.21BCNY775.21M · vs all stocks (USD)
Profit Margin
11.35%Beta
0.0160xvs all stocks
52-Week Change
-8.96%vs all stocks
Market Capitalization
15.22BCNY2.26B · vs all stocks (USD)
Enterprise Value
12.24BCNY1.82B · vs all stocks (USD)
Trailing P/E
25.76xForward P/E
16.76xPrice to Sales (TTM)
2.92xPrice to Book (MRQ)
1.69xEnterprise to Revenue
2.35xEnterprise to EBITDA
9.12xGross Margin
37.35%Profit Margin
11.35%Operating Margin
19.38%Return on Assets (TTM)
5.35%Return on Equity (TTM)
6.57%Revenue (TTM)
5.21BCNY775.21M · vs all stocks (USD)
Revenue per Share (TTM)
5.89CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-0.40%Gross Profit (TTM)
1.75BCNY260.54M · vs all stocks (USD)
EBITDA (TTM)
1.15BCNY171.29M · vs all stocks (USD)
Net Income (TTM)
591.64MCNY87.98M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-21.90%Operating Cash Flow (TTM)
1.53BCNY227.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
620.73MCNY92.31M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1000CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.60%vs all stocks
5-Year Average Dividend Yield
1.85%vs all stocks
Payout Ratio
44.78%Minority Interest (Equity)
66.48MCNYFY2025 · Dec 31, 2025Revenue
5.51BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
3.48BCNYFY2025 · Dec 31, 2025Gross Profit
2.03BCNYFY2025 · Dec 31, 2025Operating Income
1.23BCNY183.40M · vs all stocks (USD)
Pre-tax Income
919.45MCNYFY2025 · Dec 31, 2025Income Tax Expense
190.91MCNYFY2025 · Dec 31, 2025Net Income
728.54MCNYFY2025 · Dec 31, 2025EBIT
929.58MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.68BCNYFY2025 · Dec 31, 2025Research & Development
256.99MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
120.08MCNYFY2025 · Dec 31, 2025Other Operating Expenses
76.67MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
41.32MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
10.12MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.8200CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.8200CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
890.33MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
890.33MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
728.54MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.53MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
1.26BCNYFY2025 · Dec 31, 2025Free Cash Flow
600.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.46BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
728.54MCNYFY2025 · Dec 31, 2025Other Non-cash Items
26.51MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
162.65MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
337.77MCNYFY2025 · Dec 31, 2025Capital Expenditures
-654.75MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.38BCNYFY2025 · Dec 31, 2025Sale of Investments
5.02MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-2.03BCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
470.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-815.81MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-450.41MCNYFY2025 · Dec 31, 2025Other Financing Charges
-111.59MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-907.81MCNYFY2025 · Dec 31, 2025Shares Outstanding
889.45MSharesUpdated Aug 21, 2026Float Shares
477.13MSharesUpdated Aug 21, 2026% Held by Insiders
44.91%vs all stocks
% Held by Institutions
11.22%vs all stocks
Total Cash (MRQ)
2.90BCNY430.81M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.32CNYUpdated Aug 21, 2026Total Debt (MRQ)
11.12MCNY1.65M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0012xCurrent Ratio (MRQ)
3.91xBook Value per Share (MRQ)
10.20CNYUpdated Aug 21, 2026Total Assets
10.60BCNY1.58B · vs all stocks (USD)
Total Current Assets
5.54BCNYFY2025 · Dec 31, 2025Total Liabilities
1.81BCNYFY2025 · Dec 31, 2025Total Non-current Assets
5.07BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
234.78MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.58BCNYFY2025 · Dec 31, 2025Cash
1.46BCNYFY2025 · Dec 31, 2025Cash Equivalents
86.91MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.54BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.02BCNYFY2025 · Dec 31, 2025Inventory
1.42BCNYFY2025 · Dec 31, 2025Accounts Payable
1.07BCNYFY2025 · Dec 31, 2025Short-term Debt
57.57MCNYFY2025 · Dec 31, 2025Other Current Liabilities
9.50MCNYFY2025 · Dec 31, 2025Long-term Debt
6.05MCNYFY2025 · Dec 31, 2025Common Stock (Book)
889.45MCNYFY2025 · Dec 31, 2025Retained Earnings
3.32BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
8.79BCNY1.31B · vs all stocks (USD)
Treasury Stock
102.00MCNYFY2025 · Dec 31, 202552-Week Low
12.05CNYUpdated Aug 21, 202652-Week High
22.25CNYUpdated Aug 21, 202652-Week Change
-8.96%vs all stocks
Beta
0.0160xvs all stocks
50-Day MA
14.67CNYUpdated Aug 21, 2026200-Day MA
16.37CNYUpdated Aug 21, 2026Avg 10-Day Volume
49.39MSharesUpdated Aug 21, 2026Avg 30-Day Volume
35.63MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.6700CNYUpdated Aug 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.73: safe zoneNotable
Altman Z-Score: 6.73
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.26B, above the global median of $1.15BNotable
Market cap (USD): 2,263,115,635.993Global Median: 1,146,734,693.424
Revenue is $775.21M, above the global median of $520.53MNotable
Revenue (USD): 775,209,497.672Global Median: 520,528,949.311
Levered free cash flow is $92.31M, above the global median of $16.24MNotable
Levered free cash flow (USD): 92,309,365.037Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Oxford Nanopore Technologies plc
Tier 1ProductionApproval-Gated PipelineFlowInterface
Nanobiotix S.A.
Tier 1ProductionApproval-Gated PipelineRule
Pavella Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pfizer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Voronoi, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Granules India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jiangzhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Neogen Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Zai Lab Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Zozo, Inc.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With OCF Coverage And Cash Near Total Debt
Jiangxi JDL Environmental Protection Co. Ltd.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With OCF Coverage And Cash Near Total Debt
Bolsa Mexicana de Valores, S.A.B. de C.V.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash Backing With OCF Coverage And Cash Near Total Debt